The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
|Videos|November 12, 2021
Dr. Kaplan: “There’s so much going on” in BPH
Author(s)Urology Times staff
“I'm basically highlighting some of the data that's currently out there, but more importantly, some of the data that [are] just emerging,” says Steven A. Kaplan, MD.
Advertisement
In this video, Steven A. Kaplan, MD, shares talking points from his presentation at the 2021 LUGPA annual meeting. Kaplan is a professor of urology at the Icahn School of Medicine and director of the Men’s Wellness Program at Mount Sinai, New York, New York.
Advertisement
Related to this article
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.
Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.
Advertisement
Advertisement
Trending on Urology Times
1
Factors shaping PSMA-PET agent selection in prostate cancer
2
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
3
Chad Ritch, MD, on using PSMA-PET to guide treatment decisions
4
Nogapendekin alfa inbakicept plus BCG advances to final analysis in BCG-naïve NMIBC
5